thought call
announc spin lt posit add nt uncertainti
thought weak merck share drg justifi base
mix result gener in-lin guidanc uncertainti surround
announc spin-off women health/legaci busi long term view
strategi streamlin oper focu higher growth product posit
next year howev optic merck differenti growth profil
convert slower growth profil post spin inspir view inde
compound-annual-growth-rate forecast revenu ep
remainco previous period pictur look better
revenu ep compound-annual-growth-rate remainco previous
valu newco ad pictur transit period
spin mechan could domin narr differ
acceler topline/margin upside/multipl expans stori defin merck
expect signific keytruda upsid could warrant closer look share
note result light sever ou outsid us
headwind mani competit dataset poseidon
peak forecast trivial overal like strateg rational
today announc long term share could undergo volatil
clariti keytruda trajectori reiter neutral rate lower po
new methodolog base valu remainco newco
margin upsid lack near term key area discuss
much discuss focus margin profil remainco
agre case upsid longer term op margin think
investor focus nearer-term financi inde think
weak share driven expect margin declin previous
expans model op margin vs
model chang pro forma expect revenu ep
ep page addit detail
chang reflect propos spin includ full remainco newco
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
merck co global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
remain posit overal merck stori
howev neutral thesi reflect
moment rise expect
keytruda franchis expect
keytruda maintain domin posit
across i/o landscap year come see
littl room upsid current street
expect larg major higher-
impact catalyst play
million
exhibit stand-alone merck forma
net interest incom
exhibit new co forma
net interest incom
price object po base combin intrins valu remainco
newco valu remainco base
blend averag price-to-earnings multipl appli ep reflect continu
strength merck core growth franchis risk-adjust dcf wacc
termin growth rate valu newco base assum ev/ebitda
first full year repres discount vs peer reflect slow growth
risk po impress competitor readout result key i/o indic
nsclc rcc rapid declin across diabet franchis
expect neg outcom compani later-stag asset on-going
develop pressur headlin risk face sector includ drug price
reform spin-off take place
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
